盆腔肿瘤IMRT下骨髓剂量-体积参数与急性血液学毒性相关性研究进展

doi:10.11904/j.issn.1002-3070.2019.04.014

摘要/Abstract

摘要： 盆腔恶性肿瘤同期放化疗期间发生骨髓抑制的风险较高,盆腔受照射骨髓(骼)的剂量-体积关系与放化疗期间的急性血液学毒性存在相关,但缺乏此方面公认的参数。盆腔不同部位骨髓(骼)造血能力具有异质性,靠近体中轴的盆腔骨髓造血能力最强,即功能性骨髓。找准盆腔功能性骨髓的剂量-体积参数与盆腔恶性肿瘤放化疗期间急性血液学毒性的关系也许是今后发展方向。

关键词: 盆腔恶性肿瘤, 放射治疗, 骨髓抑制, 功能性骨髓, 剂量-体积

Abstract: There is a high risk of myelosuppression in pelvic malignant tumors during concurrent chemoradiotherapy.The dose-volume relationship of pelvic exposed bone marrow(bone)is related to acute hematological toxicity during radiotherapy and chemotherapy,but lacks recognized parameters in this respect.The hematopoietic capacity of the bone marrow(bone)in different parts of the pelvic cavity is heterogeneous,and the pelvic bone marrow near the central axis has the strongest hematopoietic capacity,namely functional bone marrow.The relationship between dose-volume parameters of pelvic functional bone marrow and acute hematologic toxicity during chemoradiotherapy of pelvic malignant tumors may be the future direction.

Key words: Pelvic malignant tumors, Radiotherapy, Myelosuppression, Functional bone marrow, Dose-volume

中图分类号:

R730.55

陈宏博, 余增荣, 丁小凡肖林. 盆腔肿瘤IMRT下骨髓剂量-体积参数与急性血液学毒性相关性研究进展[J]. 实用肿瘤学杂志, 2019, 33(4): 361-366.

CHEN Hongbo, YU Zengrong, DING Xiaofan, XIAO Lin. Progress of correlation between bone marrow dose-volume parameters and acute hematologic toxicity in pelvic malignant tumor[J]. Journal of Practical Oncology, 2019, 33(4): 361-366.

参考文献

1 Chen W,Zheng R,Zhang S,et al.Report of cancer incidence and mortality in China,2010[J].Ann Transl Med,2014,2(7):61.
2 Ellis RE.The distribution of active bone marrow in the adult[J].Phys Med Biol,1961,5:255-258.
3 Green DE,Rubin CT.Consequences of irradiation on bone and marrow phenotypes,and its relation to disruption of hematopoietic precursors[J].Bone,2014,63:87-94.
4 Cao X,Wu X,Frassica D,et al.Irradiation induces bone injury by damaging bone marrow microenvironment for stem cells[J].Proc Natl Acad Sci U S A,2011,108(4):1609-1614.
5 Mauch P,Constine L,Greenberger J,et al.Hematopoietic stem cell compartment:acute and late effects of radiation therapy and chemotherapy[J].Int J Radiat Oncol Biol Phys,1995,31(5):1319-1339.
6 Noticewala SS,Li N,Williamson CW,et al.Longitudinal changes in active bone marrow for cervical cancer patients treated with concurrent chemoradiation therapy[J].Int J Radiat Oncol Biol Phys,2017,97(4):797-805.
7 Mac Manus M,Lamborn K,Khan W,et al.Radiotherapy-associated neutropenia and thrombocytopenia:analysis of risk factors and development of a predictive model[J].Blood,1997,89(7):2303-2310.
8 Li C,Lu L,Zhang J,et al.Granulocyte colony-stimulating factor exacerbates hematopoietic stem cell injury after irradiation[J].Cell Biosci,2015,5:65.
9 Rose BS,Aydogan B,Liang Y,et al.Normal tissue complication probability modeling of acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy[J].Int J Radiat Oncol Biol Phys,2011,79(3):800-807.
10 Loiselle C,Koh WJ.The emerging use of IMRT for treatment of cervical cancer[J].J Natl Compr Canc Netw,2010,8(12):1425-1434.
11 Fernandez-Ots A,Crook J.The role of intensity modulated radiotherapy in gynecological radiotherapy:Present and future[J].Rep Pract Oncol Radiother,2013,18(6):363-370.
12 Wagner A,Jhingran A,Gaffney D.Intensity modulated radiotherapy in gynecologic cancers:hope,hype or hyperbole[J].Gynecol Oncol,2013,130(1):229-236.
13 Hong TS,Moughan J,Garofalo MC,et al.NRG oncology radiation therapy oncology group 0822:a phase 2 study of preoperative chemoradiation therapy using intensity modulated radiation therapy in combination with capecitabine and oxaliplatin for patients with locally advanced rectal cancer[J].Int J Radiat Oncol Biol Phys,2015,93(1):29-36.
14 Mell LK,Kochanski JD,Roeske JC,et al.Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy[J].Int J Radiat Oncol Biol Phys,2006,66(5):1356-1365.
15 Klopp AH,Moughan J,Portelance L,et al.Hematologic toxicity in RTOG 0418:a phase 2 study of postoperative IMRT for gynecologic cancer[J].Int J Radiat Oncol Biol Phys,2013,86(1):83-90.
16 Albuquerque K,Giangreco D,Morrison C,et al.Radiation-related predictors of hematologic toxicity after concurrent chemoradiation for cervical cancer and implications for bone marrow-sparing pelvic IMRT[J].Int J Radiat Oncol Biol Phys,2011,79(4):1043-1047.
17 唐滟,袁亚维.调强放疗同步化疗治疗宫颈癌血液学毒性相关因素分析[J].肿瘤防治研究,2016,43(4):277-281.
18 高丽环,杨士杰,刘孟奇.骨髓保护调强放疗与宫颈癌患者血液学不良反应的相关性[J].癌症进展,2017,15(9):1042-1044.
19 Wan J,Liu K,Li K,et al.Can dosimetric parameters predict acute hematologic toxicity in rectal cancer patients treated with intensity-modulated pelvic radiotherapy[J].Radiat Oncol,2015,10:162.
20 Jianyang W,Yuan T,Yuan T,et al.A prospective phase II study of magnetic resonance imaging guided hematopoietical bone marrow-sparing intensity-modulated radiotherapy with concurrent chemotherapy for rectal cancer[J].Radiol Med,2016,121(4):308-314.
21 Yang TJ,Oh JH,Apte A,et al.Clinical and dosimetric predictors of acute hematologic toxicity in rectal cancer patients undergoing chemoradiotherapy[J].Radiother Oncol,2014,113(1):29-34.
22 Newman NB,Sidhu MK,Baby R,et al.Long-term bone marrow suppression during postoperative chemotherapy in rectal cancer patients after preoperative chemoradiation therapy[J].Int J Radiat Oncol Biol Phys,2016,94(5):1052-1060.
23 Franco P,Ragona R,Arcadipane F,et al.Dosimetric predictors of acute hematologic toxicity during concurrent intensity-modulated radiotherapy and chemotherapy for anal cancer[J].Clin Transl Oncol,2017,19(1):67-75.
24 Lee AY,Golden DW,Bazan JG,et al.Hematologic nadirs during chemoradiation for anal cancer:temporal characterization and dosimetric predictors[J].Int J Radiat Oncol Biol Phys,2017,97(2):306-312.
25 Sini C,Fiorino C,Perna L,et al.Dose-volume effects for pelvic bone marrow in predicting hematological toxicity in prostate cancer radiotherapy with pelvic node irradiation[J].Radiother Oncol,2016,118(1):79-84.
26 Rose BS,Liang Y,Lau SK,et al.Correlation between radiation dose to ¹⁸F-FDG-PET defined active bone marrow subregions and acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy[J].Int J Radiat Oncol Biol Phys,2012,83(4):1185-1191.
27 Yagi M,Arentsen L,Shanley RM,et al.A dual-radioisotope hybrid whole-body micro-positron emission tomography/computed tomography system reveals functional heterogeneity and early local and systemic changes following targeted radiation to the murine caudal skeleton[J].Calcif Tissue Int,2014,94(5):544-552.
28 Shyh-Chang N,Daley GQ,Cantley LC.Stem cell metabolism in tissue development and aging[J].Development,2013,140(12):2535-2547.
29 Yagi M,Froelich J,Arentsen L,et al.Longitudinal FDG-PET revealed regional functional heterogeneity of bone marrow,site-dependent response to treatment and correlation with hematological parameters[J].J Cancer,2015,6(6):531-537.
30 Vesselle H,Grierson J,Peterson LM,et al.¹⁸F-Fluorothymidine radiation dosimetry in human PET imaging studies[J].J Nucl Med,2003,44(9):1482-1488.
31 Agool A,Schot BW,Jager PL,et al.¹⁸F-FLT PET in hematologic disorders:a novel technique to analyze the bone marrow compartment[J].J Nucl Med,2006,47(10):1592-1598.
32 McGuire SM,Menda Y,Ponto LL,et al.A methodology for incorporating functional bone marrow sparing in IMRT planning for pelvic radiation therapy[J].Radiother Oncol,2011,99(1):49-54.
33 McGuire SM,Menda Y,Ponto L,et al.Spatial mapping of functional pelvic bone marrow using FLT PET[J].J Appl Clin Med Phys,2014,15(4):129-136.

[1]	李珊,赵春波,乔文波. 术中放疗在胰腺癌中的应用进展[J]. 实用肿瘤学杂志, 2019, 33(3): 280-283.
[2]	张攀, 张迪综述, 戴晓波审校. 复发鼻咽癌再程放射治疗的研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 92-96.
[3]	杜夜生, 胡松柳, 徐向英. 非小细胞肺癌寡转移的立体定向放射治疗研究[J]. 实用肿瘤学杂志, 2018, 32(2): 154-158.
[4]	孙明亮, 徐建宇, 徐向英. 早期非小细胞肺癌立体定向放疗的相关研究[J]. 实用肿瘤学杂志, 2018, 32(1): 53-56.
[5]	刘国慧, 谷安鑫, 殷洪涛, 曹阳, 贺云龙, 王春波, 鄂明艳. 原苏木素A对胃癌SGC-7901细胞系放疗增敏作用的研究[J]. 实用肿瘤学杂志, 2017, 31(6): 500-505.
[6]	赵永瑞, 徐建堃审校. PET/MRI在高级别脑胶质瘤放射治疗中的应用[J]. 实用肿瘤学杂志, 2017, 31(6): 564-568.
[7]	罗佳宁, 郝春成, 张建鑫, 卢江岳, 葛晓峰. 术后辅助放疗对三阴性乳腺癌患者预后的影响[J]. 实用肿瘤学杂志, 2017, 31(5): 411-416.
[8]	王赫隆, 云惟康, 王业伟, 冯丽娜, 白彦灵. 三种照射技术在髓母细胞瘤放射治疗中的剂量学分析[J]. 实用肿瘤学杂志, 2017, 31(5): 436-440.
[9]	陈子印, 钱茂森, 潘慧莹. 非共面野在早期非小细胞肺癌立体定向放射治疗方面的剂量学优势[J]. 实用肿瘤学杂志, 2017, 31(2): 142-146.
[10]	曲媛媛，徐向英，庄明，殷洪涛，胡松柳，王春波，曹阳. 尼妥珠单抗对肺癌A549细胞系的体外放射增敏效应[J]. 实用肿瘤学杂志, 2016, 30(6): 497-501.
[11]	吴煜良，何松美，张纯，吴伟艺，崔顺景，赵艳海. 迭代次数在宫颈癌术后调强放疗计划中对子野权重优化的影响[J]. 实用肿瘤学杂志, 2016, 30(6): 507-510.
[12]	刘伟综述, 李惠艳审校. 表皮生长因子受体与放射敏感性关系的研究进展[J]. 实用肿瘤学杂志, 2016, 30(3): 275-278.
[13]	师镘茹综述, 鄂明艳审校. 乳腺癌亚型对放疗反应及潜在放疗敏感性的影响[J]. 实用肿瘤学杂志, 2016, 30(2): 154-157.
[14]	罗红雨, 李嘉琪, 栾瑾微, 张思亮综述, 李香兰审校. 三阴性乳腺癌放射治疗的研究进展[J]. 实用肿瘤学杂志, 2016, 30(2): 180-183.
[15]	刘纤, 任刚, 李莉琴, 朱夫海, 夏廷毅. 胰腺癌螺旋断层调强放疗高剂量少分次模式的胃肠毒副反应相关因素分析[J]. 实用肿瘤学杂志, 2015, 29(6): 481-486.